{"id":996884,"date":"2026-08-20T07:34:18","date_gmt":"2026-08-20T11:34:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cerenome-highlights-presentations-at-the-2026-sno-asco-cns-metastases-conference-demonstrating-progress-in-both-therapeutics-and-diagnostics-business-lines\/"},"modified":"2026-08-20T07:34:18","modified_gmt":"2026-08-20T11:34:18","slug":"cerenome-highlights-presentations-at-the-2026-sno-asco-cns-metastases-conference-demonstrating-progress-in-both-therapeutics-and-diagnostics-business-lines","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cerenome-highlights-presentations-at-the-2026-sno-asco-cns-metastases-conference-demonstrating-progress-in-both-therapeutics-and-diagnostics-business-lines\/","title":{"rendered":"Cerenome Highlights Presentations at the 2026 SNO\/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines"},"content":{"rendered":"
\n

\n Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal\u00a0<\/em>\u00a0\u00a0<\/p>\n

\n CNSide\u00ae cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs<\/em>\n <\/p>\n

HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) — Cerenome,<\/strong>\u00a0Inc. (Nasdaq: CNSY) (\u201cCerenome\u201d or the \u201cCompany\u201d)<\/strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology\/American Society of Clinical Oncology (SNO\/ASCO) CNS Metastases Conference, held August 13\u201315 in Boston. One presentation featured updated pharmacokinetic (PK), pharmacodynamic (PD), dosimetry, safety and activity data for REYOBIQ\u2122 (rhenium-186 obisbemeda) in patients with leptomeningeal metastases (LM), including emerging safety data from the ongoing repeated-dosing program. The second was an update of a previously reported health economics analysis evaluating the impact of CNSide\u00ae-enabled earlier LM detection and therapeutic management.<\/p>\n

\u201cThe data presented at SNO\/ASCO underscore the rationale behind Cerenome\u2019s integrated approach to leptomeningeal metastases \u2013 from earlier and more definitive detection and quantitative disease monitoring with CNSide, to targeted local therapy with REYOBIQ,\u201d said Marc H. Hedrick, M.D., Cerenome President and Chief Executive Officer. \u201cThe REYOBIQ findings provide additional support for broad CSF distribution, limited systemic exposure in most patients, and the continued evaluation of repeat dosing. The CNSide analysis reinforces the potential economic value of earlier, information-rich disease management. Together, these data demonstrate the potential of connecting diagnostics, therapeutics and longitudinal data to improve the management of CNS cancers.\u201d<\/p>\n

As previously announced, both posters will be available on the Publications page of Cerenome\u2019s website following the conclusion of the conference.<\/p>\n

\n REYOBIQ ReSPECT-LM and ReSPECT-LMM Data<\/strong>\n <\/p>\n

A poster titled,\u00a0\u201cReSPECT-LM: Pharmacokinetic and Pharmacodynamic Assessment of Rhenium Obisbemeda in Leptomeningeal Metastases with Emerging Data from Repeated Dosing (ReSPECT-LMM)\u201d\u00a0was presented by Andrew Brenner, M.D., Ph.D., of The University of Texas Health Science Center at San Antonio. The analysis included updated safety, activity, PK and dosimetry findings from the single-administration study, along with emerging data from the ongoing repeated-dosing program.<\/p>\n

Key findings included:<\/p>\n